Thalidomide: Present and future in multiple myeloma

Expert Review of Anticancer Therapy

Volumn 5, Issue 1, 2005, Pages 25-31

  Hussein, Mohamad A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Immune therapy; Multiple myeloma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2B INTERFERON; ANTHRACYCLINE; ANTIHISTAMINIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C19; DEXAMETHASONE; DOCUSATE SODIUM; DOXORUBICIN; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PARAPROTEIN; PROTEASOME INHIBITOR; STEROID; THALIDOMIDE; VASCULOTROPIN; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTRACEPTION; CYANOCOBALAMIN DEFICIENCY; DEEP VEIN THROMBOSIS; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FOLLOW UP; HUMAN; HYPOTENSION; IMMUNOMODULATION; INFECTION; KAPLAN MEIER METHOD; LEUKOPENIA; MORTALITY; MULTIPLE MYELOMA; MUSCLE WEAKNESS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PLASMA CELL DYSCRASIA; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIATION EXPOSURE; RELAPSE; REVIEW; RISK FACTOR; SOMNOLENCE; STEM CELL TRANSPLANTATION; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; TERATOGENICITY; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; THALIDOMIDE;

EID: 14244259187     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.1.25     Document Type: Review

References (58)

1. Avet-Loiseau H, Facon T, Daviet A et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 59, 4546-4550 (1999).
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121, 749-757 (2003).
3. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J. Clin. 53, 5-26 (2003).
4. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol. Oncol. Clin. North Am. 6, 225-247 (1992).
5. Brown LM, Gridley G, Pottern LM et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control 12, 117-125 (2001).
6. Hussein MA, George R, Rybicki L, Karam MA. Skeletal trauma preceding the development of plasma cell dyscrasia: eight case reports and review of the literature. Med. Oncol. 20, 349-354 (2003).
7. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571 (1999).
8. Hussein MA. Thalidomide, age, and future use in multiple myeloma. Blood 102, 2-b (2003).
9. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 104, 607-618 (2004).
10. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20, 4319-4323 (2002).
11. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21, 16-19 (2003).
12. Warren NJ, Celgene Corp. Thalomid capsules (thalidomide) prescription product insert. (1998).
13. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 55, 1827-1834 (1998).
14. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 363, 1802-1811 (2004).
15. Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Ann. Rev. Med. 53, 629-657 (2002).
16. Chen TL, Vogelsang GB, Petty BG et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab. Dispos. 17, 402-405 (1989 ).
17. Raje N, Anderson K. Thalidomide - a revival story. N. Engl. J. Med. 341, 1606-1609 (1999).
18. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Med. 5, 582-585 (1999).
19. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82, 3712-3720 (1993).
20. Chauhan D, Uchiyama H, Akbarali Y et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 87, 1104-1112 (1996).
21. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91, 3-21 (1998).
22. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658-1667 (1999).
23. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31, 213-221 (1996).
24. Vacca A, Ribatti D, Presta M et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064-3073 (1999).
25. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59, 728-733 (1999).
26. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082-4085 (1994).
27. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64, 971-978 (1997).
28. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13, 469-472 (1999).
29. Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87, 503-508 (1994).
30. Vacca A, Di LM, Ribatti D et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LEA-1, VLA-4, LAM-1, and CD44. Am. J. Hematol. 50, 9-14 (1995).
31. Vacca A, Ribatti D, Roncali L, Dammacco F. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk. Lymphoma 20, 27-38 (1995).
32. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood 98, 492-494 (2001).
33. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 80, 887-890 (1992).
34. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann. Intern. Med. 105, 8-11 (1986 ).
35. Hussein MA, Wood L, Hsi E et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 95, 2160-2168 (2002).
36. Rifkin RM. Updated results from a randomized multicenter trial of DVd vs. VAd in patients with newly diagnosed multiple myeloma. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 23).
37. Agrawal N. Pegylated doxorubicin (D), vincristine (V), reduced frequency dexamethasone (D) and thalidomide (T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. (2003).
38. Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist 8(Suppl. 3), 39-45 (2003).
39. Srkalovic G, Elson P, Trebisky B, Karam MA, Hussein MA. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med. Oncol. 19, 219-226 (2002).
40. Kropff MH, Lang N, Bisping G et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br. J. Haematol. 122, 607-616 (2003).
41. Moehler TM, Neben K, Benner A et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98, 3846-3848 (2001).
42. Mileshkin L, Biagi JJ, Mitchell P et al. Multicenter Phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102, 69-77 (2003 ).
43. Palumbo A, Bertola A, Falco P et al. Efficacy of low-dose thalidomide and dexamethasone as firt salvage regimen in multiple myeloma. Hematol. J. 5, 318-324 (2004).
44. Srkalovic G, Cameron MG, Rybicki L et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101, 558-566 (2004).
45. Zangari M, Barlogie B, Anaissie E et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol. 126, 715-721 (2004).
46. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol. 35, 969-979 (1996).
47. Hussein MA. Research on thalidomide in solid tumors, hematologic malignancies, and supportive care. Oncology (Huntingt) 14, 9-15 (2000).
48. Baz R, Alemany C, Green R, Hussein MA. Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer 101, 790-795 (2004).
49. Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J. Am. Acad. Dermatol. 48, 548-552 (2003).
50. Huang SY, Tang JL, Yao M et al. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann. Hematol. 82, 558-564 (2003).
51. Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 87, 408-414 (2002).
52. Berenson JR, Crowley JJ, Grogan TM et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99, 3163-3168 (2002).
53. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S. T. E. P. S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. 21, 319-330 (1999).
54. Neben K, Moehler T, Benner A et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin. Cancer Res. 8, 3377-3382 (2002).
55. Yakoub-Agha I, Attal M, Dumontet C et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol. J. 3, 185-192 (2002).
56. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. 121, 768-771 (2003).
57. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J. Clin. Oncol. 10, 334-342 (1992).
58. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol. 16, 3832-3842 (1998).